Fierce Biotech article highlights dearth of inclusion in

An important article from industry publication Fierce Biotech highlights the lack of inclusion of the Down syndrome community in Alzheimer’s research. LuMind

Fierce Biotech's 2022 Fierce 15

In setback, a majority of FDA experts reject Sarepta's emotional campaign to gain Duchenne drug OK

Fierce Biotech Summit

A new age of precision gene therapy - The Lancet

Women at BIO say 'I'm here to do my job' despite toxic tropes

Fierce Biotech article highlights dearth of inclusion in Alzheimer's research - LuMind IDSC Foundation

Healthcare Industry News Weekly Wrap-Up: July 28, 2022

Fierce Healthcare's 2023 Women of Influence

Biopharma digital transformation

Increasing clinical trial diversity